OBJECTIVE: To evaluate the clinical effectiveness of pemetrexed combined with cisplatin for
the first-line chemotherapy of patients with advanced non-small-cell lung cancer (NSCLC) …

Background We evaluated the safety and efficacy of induction chemotherapy with
bevacizumab followed by maintenance chemotherapy with bevacizumab for advanced non …

8044 Background: Pemetrexed in combination with carboplatin has been shown to have
promising activity, particularily in adenocarcinoma and large cell carcinoma, as well as …

The present study evaluated the efficacy and safety of pemetrexed, carboplatin and
bevacizumab, followed by maintenance pemetrexed and bevacizumab, in chemotherapy …

Background Pemetrexed has emerged as one of the most active agents for the treatment of
patients with advanced non-small cell lung cancer (NSCLC). We conducted a phase II study …

Background: Platinum-based chemotherapy is the standard of care for first-line treatment of
locally advanced and metastatic NSCLC. Gemcitabine-cisplatin (GC) is a widely used …

Introduction Lung cancer accounts for 20% of cancer deaths in Spain. The most frequent
subtype (87%) is non-small cell lung cancer (NSCLC). Pemetrexed is a recently marketed …

INTRODUCTION: This randomized, open-label study compared pemetrexed versus
docetaxel as second-line therapy for Chinese patients with locally advanced or metastatic …

Locally advanced non-small cell lung cancer (NSCLC) continues to be a challenging
disease to treat. With high rates of both local and distant failures, there is significant interest …

LBA7727 Introduction: The mild toxicity profile of pemetrexed (P), seen in a phase III trial of P
500 mg/m2 vs docetaxel 75 mg/m2 in vitamin-supplemented patients (pts), suggests higher …